HOME >> BIOLOGY >> NEWS
CTRC enrolls first patients in novel phase II study for sarcoma -- living virus destroys cancer cell

udy was diagnosed with breast cancer in April 2005 and 11 months later received an additional diagnosis for a rare form of sarcoma. A specialist at the Dana-Farber Cancer Institute in Boston referred her to CTRC, where Mita suggested the REOLYSIN study. After discussing it with her family and doctor, she decided it was the best treatment option for her.

This new therapy gives me another option in the fight against my cancer, said the 35-year-old mother of three who travels to San Antonio for treatment with her husband and children. Before coming to CTRC, I had already been through one chemotherapy cycle for this disease, and I got the impression that no one really knew what to do with me or how to treat my cancer. REOLYSIN was a less toxic option for me.

"We are delighted, but not surprised, with the rate of accrual at the CTRC Institute for Drug Development, said Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. As an evolving oncology company, the placement of Oncolytics very innovative and sophisticated studies is of critical importance and we are delighted to have the CTRC Institute for Drug Development as our collaborator. This study is expected to yield information that will guide the late stage clinical development program for REOLYSIN.

REOLYSIN demonstrated success against tumors during earlier phases of scientific testing. This study (REO 014) is a Phase II, open-label, single agent study with the primary objective of measuring tumor responses and the duration of those responses, and of describing any evidence of anti-tumor activity. REOLYSIN will be given intravenously to patients for five consecutive days. Patients may receive additional five-day cycles of therapy every four weeks for a maximum of eight cycles. Up to 52 patients will be enrolled in the study.


'"/>

Contact: Jill. B. Byrd
jbyrd@ctrc.net
210-450-5550
Cancer Therapy & Research Center (CTRC)
24-Jul-2007


Page: 1 2

Related biology news :

1. Saudi Arabias KAUST names WHOI first research partner
2. Which came first, the moth or the cactus?
3. In a first, Einstein scientists discover the dynamics of transcription in living mammalian cells
4. Seawater intrusion is the first cause of contamination of coastal aquifers
5. Camera-shy deer caught for first time
6. New joint replacement material developed at MGH put to first clinical use
7. Liverpool amongst first in UK to install unique DNA sequencing technology
8. A first-principles model of early evolution
9. Worlds first X-ray free electron laser is on course to completion
10. Scientists identify first gene linked to scoliosis
11. Which came first: Primates ability to see colorful food or see colorful sex?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: